Navigation Links
Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
Date:3/31/2008

the reduction in fatal strokes is an important finding.

Emeritus Professor Christopher Bulpitt, the lead investigator on the study from the Care of the Elderly Group at Imperial College London, said: "Before our study, doctors were unsure about whether very elderly people with high blood pressure could see the same benefits from treatment to lower their blood pressure as those we see in younger people. Our results clearly show that many patients aged 80 and over could benefit greatly from treatment. Populations are living longer and we have growing numbers of people living well into their 80s and beyond, so this is good news. We are very pleased that cardiovascular events were reduced safely with a reduction in total mortality."

The researchers hope that their findings will clear up uncertainty amongst clinicians about the benefits of treating those aged 80 and over for high blood pressure.

Dr Nigel Beckett, the trial co-ordinator from the Care of the Elderly Group at Imperial College London, added: "Many very elderly people with high blood pressure are not being treated for it at the moment, because doctors are unsure about whether or not treatment will help them. We hope that following our study, doctors will be encouraged to treat such patients in accordance with our protocol."

As the trial was stopped early, an extension involving patients receiving active-treatment is now underway to assess the longer term benefits of treatment.

Patients with high blood pressure (defined here as a systolic blood pressure between 160-199 mmHg), from thirteen countries across the world, were randomised for the double-blind, placebo-controlled trial, which began in 2001. The mean age of participants was 83 years and 7 months.

Patients were given either placebo or indapamide slow release (SR) with the addition of perindopril, in tablet form once a day as required, to achieve a target blood pressure of 150/80 mmHg. The average follow-up of
'/>"/>

SOURCE Imperial College London
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
2. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
3. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
4. InterMune to Present at the SIGnificant Options in Healthcare Conference
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
10. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
11. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolyti...SX:ONC; NASDAQ: ONCY ) announced today that in con...g, the underwriters have exercised in full their o...37,500 units. Each unit is comprised of one common... and was sold at a price of US$3.00 per unit. Each...
(Date:12/2/2009)... JERUSALEM, Israel, December 2 Gamida Cell an...reclinical (animal study) safety and,efficacy of a...om Weill,Cornell Medical College and Gamida Cell. ...anemias such as Cooley,s Anemia. , Gamida Cell... ex vivo,populations of stem/progenitor cells. The...
(Date:12/2/2009)... CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zen...y"), a global biopharmaceutical company focused on...hat the U.S. Food and Drug Administration (FDA) ha... PI3K/Akt pathway inhibitor compound, perifosine (...y multiple myeloma. Keryx Biopharmaceuticals, Inc....
(Date:12/1/2009)... Dr. Kerry Solomon announced that he ...nched his redesigned website at www.DrKerrySolomo...Group. Dr. Solomon is a proven LASIK, lens implan...sionally recognized for his substantial contributi... a member of Trusted LASIK Surgeons, which screens...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
..., March 13 /PRNewswire-FirstCall/ -- DOR BioPhar...mpany) announced today that it has appointed Brian...d Chief Medical Officer. Dr. Hamilton is a recogni...ally active steroids as well as in Graft-versus-Ho...shed career of more than 25 years in both academia...
... Some of the world,s most respected e...security questions during a daylong gathering in H...eater Houston Partnership once again takes center ...hosting "America,s Energy Future: Assessing O... Houston (PRWEB) March 13, 2009 -- Pres...
... N.J., March 12 Schering-Plough Corporation (NYSE...arnings results for the 2009 first quarter on Tues...that day, Schering-Plough will conduct a conferenc...r. Fred Hassan, Schering-Plough,s chairman and CE...onference call. , , To listen live to the call, ...
Other Biology Technology:DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 2DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 3DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 4DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 5Greater Houston Partnership to Lead Energy Security Discussion 2
(Date:12/3/2009)...mes to investment in energy efficient technologies...esearch Council (EPSRC) Chief Executive Dave Delpy...ineering research has already brought us fuel cell...e investment is needed to develop the capabilities...on emission targets by 2020 and limit the impact o...
(Date:12/2/2009)...strengthen the evidence that people who smoke ciga...d risk for developing colorectal cancer, even afte...ides one more reason not to smoke, or to quit as s...un, M.D., M.S., vice president emeritus, epidemiol...er Society. "Colorectal cancer should be added to ...
(Date:12/2/2009)...er-free status did not prompt people participating...cancer screening program to pick up their cigarett...n Cancer Epidemiology, Biomarkers & Prevention , ...esearch. The December issue contains a special foc...espread concern in the lung screening community th...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Questions to Pharmacists Rise After Michael Jacksons Death 51194 1Questions to Pharmacists Rise After Michael Jacksons Death 51194 2Universal Health Services Inc Announces Dividend 51192 1Data published in the New England Journal of Medicine support use of raxibacumab 28ABthrax 29 for the treatment of inhalation anthrax 9185 1Data published in the New England Journal of Medicine support use of raxibacumab 28ABthrax 29 for the treatment of inhalation anthrax 9185 2
...ose of chemotherapy drugs to specific cancer cells... may one day be possible thanks to a nanoscale dru... the U.S. Department of Energy,s Ames Laboratory. ...spheres to carry drugs inside living cells, Ames L... methods to control whether or not the particle de...
...ene-coated gold particles protect mice against a p...ers at UT Southwestern Medical Center have found. ...roducing the specific protein ?called amyloid-beta...odies and greatly reduce the protein,s build-up in...ans is a hallmark of Alzheimer,s disease. , "The ...
...hool of Medicine researchers have identified the p...e first line of defense against invading pathogens...site this week and will be published in a future i...re body is formed in the skin by a group of cells ...gens present in the skin and transport them to lym...
Other Biology News:Cellular scale drug delivery from the inside out 2Cellular scale drug delivery from the inside out 3DNA gene vaccine protects against harmful protein of Alzheimer's disease 2Source of crucial immune cell in the skin discovered 2
Feline serum from Equitech-Bio
Donor feline Serum - 500mL from Biomeda Corporation
Paraffin Tissue Section Panel - Monkey (Simian) Normal Tissue, Multi-tissue I from BioChain
Mouse Anti-Rabbit ryanodine receptor, skeletal Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: